Pfizer and BioNTech announced Wednesday that their coronavirus vaccine was found to be 100%reliable at safeguarding versus COVID-19 in a trial of more than 2,200 children between the ages of 12 and 15.
The big image: Pfizer CEO Albert Bourla stated the companies plan to send medical trial data to the FDA for emergency use permission in the coming weeks, with the hope of vaccinations for adolescents starting prior to the start of the next academic year.
- The trial’s information will likewise be submitted to the European Medicines Agency (EMA) for emergency usage authorization.
What they’re saying: “Around the world, we are yearning for a typical life. This is specifically true for our children,” said Ugur Sahin, CEO and co-founder of BioNTech.
- ” The initial results we have actually seen in the teen research studies recommend that kids are especially well secured by vaccination, which is really encouraging offered the patterns we have seen in current weeks relating to the spread of the B. 1.1.7 UK variant,” he included.
Details: The medical trial was carried out in the U.S. with 2,260 adolescents ages 12 to15
- The vaccines highlighted “100?ficacy and robust antibody responses,” and accomplished much better results than a previous research study performed on 16-25 year olds.
- 18 cases of COVID-19 were observed in the group of individuals who received a placebo, while none were observed in those who were immunized.
- Pfizer and BioNTech also announced that the very first doses were administered recently in a trial of kids ages 6 months to 11 years
No comments:
Post a Comment